Topics In Demand
Notification
New

No notification found.

Empowering Pharmacovigilance with AI: Pioneering a Safer Tomorrow through Data-Driven Insights.
Empowering Pharmacovigilance with AI: Pioneering a Safer Tomorrow through Data-Driven Insights.

September 14, 2023

76

1

Highlights:
  • In healthcare, drug safety is paramount, and pharmacovigilance is the unsung hero. AI steps in as the game-changer amidst growing data complexity.
  • Managing the tsunami of data – adverse event reports, patient narratives, and social media discussions – is daunting, demanding timely and accurate handling.
  • AI is the silver bullet. It processes data 300 times faster, identifies adverse events with 95% accuracy, and slashes analysis time by 80%.
  • However, as with any technology, pharmaceutical companies must adopt a strategic approach when integrating AI and defining the anticipated outcomes. One of the key priorities is the rationalization and optimization of data.

In the complex world of healthcare, ensuring drug safety is a paramount concern. One of the unsung heroes in this endeavor is pharmacovigilance, the science of monitoring and assessing the safety of medications once they hit the market. But as our understanding of drug safety grows, so does the volume and complexity of pharmacovigilance data. That’s where AI steps in. Join us on this enlightening journey as we delve into how AI is revolutionizing pharmacovigilance, making it more efficient, responsive, and patient-centric. Together, let’s uncover how these data-driven insights are shaping a safer and more promising future for healthcare worldwide.

The Crucial Role of Pharmacovigilance

Pharmacovigilance is the science and practice of monitoring and assessing medication safety once available to the public. Its primary goal is to identify and prevent adverse effects, making sure that patients receive the best and safest treatments possible. This discipline plays an indispensable role in healthcare, ensuring that drugs continue to benefit patients while minimizing potential harm. 

Lately, the global pharmacovigilance scene has been growing at an exponential rate, showing how vital it is. Back in 2020, it was worth about $5.56 billion, and now experts say it could hit a whopping $14.85 billion by 2028. That big jump shows that more and more people are recognizing how crucial pharmacovigilance is. Part of the reason for this growth is the rise in chronic diseases like heart problems, diabetes, and cancer, plus the use of digital health records and tech. Also, more clinical trials and the demand for personalized medicine are making pharmacovigilance even more important. But those numbers are just the start of the story. In 2021, the World Health Organization (WHO) got a whopping 10 million Individual Case Safety Reports of suspected bad reactions to drugs, and sadly, over 100,000 folks didn’t make it due to these reactions. These numbers sound pretty scary, right? That’s why we’ve got pharmacovigilance – it keeps a close watch and figures out when medicines might be causing problems. It doesn’t just point out issues; it also looks at the overall pros and cons of medicines. And when it spots something going wrong, it acts fast to protect patients. It’s the safety net for our healthcare, making sure medicines do more good than harm.

The Data Dilemma

As healthcare systems have become increasingly digitized, the volume and complexity of pharmacovigilance data have surged to unprecedented levels. Adverse event reports, patient narratives, electronic health records (EHRs), and even social media discussions all contribute to this data tsunami. It’s a treasure trove of valuable information but also a challenge to manage. This data is the lifeblood of drug safety. But here’s the catch – it’s a beast to handle.

Why, you ask? Well, imagine sifting through millions of patient narratives, deciphering handwritten doctor notes, and parsing through endless streams of social media chatter. It’s like searching for a needle in a haystack while blindfolded. Let’s break down some numbers here!

  • Back in 2022, around 75 million ICSRs (that’s Individual Case Safety Reports) made their way into the global pharmacovigilance databases. 
  • Also, 2022 witnessed a staggering 150 billion clinical notes and a whopping 100 billion lab results from electronic health records (EHRs). And if you peek inside the average EHR, you’ll find information on more than 100,000 patients.
  • Now, looking ahead to 2023, estimates suggest that there will be more than half a million patients taking part in these trials all around the world. 

These are just a few examples highlighting the massive amount of data pouring in, and there’s even more that hasn’t been processed yet! Check this out, in 2022, pharmaceutical companies generated a mind-boggling 100 zettabytes of data. To put that in perspective, it’s like having the data from a whopping 100 trillion hard drives. And by 2025, experts predict this number will skyrocket to 440 zettabytes! Timely and accurate pharmacovigilance of this data is the bedrock of healthcare decision-making, but the sheer volume and complexity can be overwhelming. Also, one cannot miss the cost of managing and maintaining all this data. Just storing and maintaining electronic health records (EHR) data is no small expense – it’s predicted to hit around $100 billion annually. Looking ahead, by 2024, it’s expected that the whole world will spend a whopping $25 billion on pharmacovigilance. That’s a lot of money, no doubt!

This is precisely where Artificial Intelligence (AI) comes to the rescue. AI is not just a buzzword; it’s a powerful tool that has the potential to transform pharmacovigilance in remarkable ways. AI can process and analyze vast datasets with speed and accuracy, making it an invaluable asset in the quest for drug safety.

  • AI can process pharmacovigilance data up to 300 times faster than manual methods.
  • Machine learning algorithms can identify adverse events in unstructured data, such as patient narratives, with an accuracy of up to 95%.
  • AI has the potential to reduce the time required for signal detection and data analysis by as much as 80%.

 


That the contents of third-party articles/blogs published here on the website, and the interpretation of all information in the article/blogs such as data, maps, numbers, opinions etc. displayed in the article/blogs and views or the opinions expressed within the content are solely of the author's; and do not reflect the opinions and beliefs of NASSCOM or its affiliates in any manner. NASSCOM does not take any liability w.r.t. content in any manner and will not be liable in any manner whatsoever for any kind of liability arising out of any act, error or omission. The contents of third-party article/blogs published, are provided solely as convenience; and the presence of these articles/blogs should not, under any circumstances, be considered as an endorsement of the contents by NASSCOM in any manner; and if you chose to access these articles/blogs , you do so at your own risk.


© Copyright nasscom. All Rights Reserved.